Targeted Protein Degradation Therapeutics Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2030

The global market value of the targeted protein degradation therapeutics market was valued at USD 450.5 million in 2022, and a CAGR of 26.7% is expected during the forecast period. Protein degradation is generally a process in which proteins are generally destroyed in cells.  It is a pharmacological perception that grants practical drug development chances and is expected to announce a new paradigm in modern therapeutic interventions. Increasing awareness among the people about protein degradation and increasing demand for protein degradation for drug discovery strategies to treat diseases. Increasing demand for immunoassays to diagnose and detect microorganism-based infections.

Growing acceptance of advanced technology is driving the demand in the targeted protein degradation therapeutics market. Patients and healthcare providers are increasingly seeking personalized treatment options that are more effective and have fewer side effects. TDP therapies offer a targeted approach that aligns with the goals of precision medicine. As scientific understanding of protein homeostasis and degradation pathways improves, researchers are identifying new therapeutic targets. This knowledge is translating into new drug development opportunities. Increasing campaigns by governments all over the world are driving growth in the market. Rising healthcare expenditure and increasing emphasis on diagnosing and treating chronic diseases in an effective and efficient manner are the need of the hour.

Growth Drivers

The development of new technologies and techniques in drug discovery, including those related to TDP, is a major growth driver. Innovations in protein degradation technology and the rising prevalence of chronic diseases are driving growth in the market. The increasing prevalence of cancer, neurogenerative disorders, and autoimmune diseases is the main cause behind the growth in the market. Growing investment and funding from venture capital firms, pharmaceutical companies, and government organizations are supporting the research and development. Increased focus on personalized medicine is driving the need for targeted therapies and driving the growth in the market. Collaboration between biotech firms and pharmaceutical companies is accelerating the development.

For many diseases, including cancer, neurogenerative disorders, and autoimmune diseases, there is a very limited treatment option. This technique offers a novel approach to target disease-causing proteins that are currently considered "undruggable." Innovations in protein degradation technologies, such as PROTACs, and molecular glues have accelerated the development of new therapies. These advancements make it possible to selectively degrade specific proteins rather than just inhibiting them. Pharmaceutical companies and biotech firms are heavily investing in research and development, and licensing deals between biotech companies and large pharmaceutical firms are driving growth in the market significantly.

Regulatory agencies like the FDA have shown support for innovative therapies in areas of high unmet need, including TDP therapies. Fast track designation and other incentives are encouraging companies to bring these companies to market more quickly. Initially focused only on cancer, TDP is now being explored for a broader range of diseases. This expansion into areas like neurodegeneration and autoimmune diseases is opening up new markets and driving growth. The growth of biotech hubs in regions like North America, Europe, and Asia is fostering innovation and collaboration in the TDP field, contributing to the market expansion.

Segmentation

By Drug Type

·         Proteolysis Targeting Chimeras

·         Molecular Glues

·         Lysosomes Targeting Chimeras

·         Autophagy Tethering Compounds

By Therapeutic Indication

·         Oncology

·         Immunology

·         Neurogenerative Disorders

·         Infectious Diseases

·         Rare Diseases

By End-User

·         Pharmaceuticals

·         Biotechnology Companies

·         Academic and Research Institutes

·         Contract Research Organizations

Regional Outlook

·         Asia Pacific

·         North America

·         Latin America

·         Europe

·         Middle East and Africa

Targeted Protein Degradation Therapeutics Market by Therapeutic Indication

On the basis of the therapeutic indication, the targeted protein degradation therapeutics market is segmented into oncology, immunology, rare diseases, neurogenerative disorders, and infectious diseases. Cancer remains one of the most challenging and prevalent diseases worldwide. Despite advancements in treatment, many cancers have limited therapeutic options, especially for patients with advanced forms of diseases. TDP offers a novel approach to target oncogenic proteins that are difficult to inhibit with traditional therapies.

Many cancers are driven by specific proteins that promote tumor growth and survival. TDP allows for the selective degradation of these proteins, leading to more effective treatments with fewer off-target effects compared to conventional therapies. The oncology sector receives substantial investment from pharmaceutical companies and research institutions. Regulatory agencies like the FDA and EMA offer incentives for the development of cancer therapies, such as orphan drug designations. These therapies are used in combination with existing combinations such as chemotherapy, targeted therapies, and immunotherapies. Diversity of cancer types and the variety of oncogenic proteins implicated in different cancers provide numerous targets for TDP therapies.

 Regional Outlook

On the basis of the regions, the targeted protein degradation therapeutics market is segmented into 5 parts: Asia Pacific, North America, Latin America, the Middle East and Africa, and Europe. North America is the leading segment in the market and is expected to dominate the region during the forecast period. Increasing geriatric population and increasing prevalence of chronic diseases are driving growth in the market significantly. The increasing number of cancer patients and the best healthcare infrastructure in the United States, along with Canada, is driving growth in the market significantly.

Increased focus on personalized medicine is driving growth in the market. Collaboration between biotechnological firms and research institutes in North America is driving growth in the market. The presence of key players in the North American region is driving growth in the market significantly. Asia Pacific is one of the leading segments in the market due to its large population, and the increasing number of cancer patients in the region, as well as other chronic diseases, is driving growth in the market. Growing investment and funding from pharmaceutical companies are driving the growth in the market.

Increasing demand for immunoassay in the region is driving growth in the market significantly. Increasing demand to prevent the diseases due to microorganisms. European region, including countries like Germany, France, Russia, England, Italy, and other countries, due to the better healthcare infrastructure is witnessing growth during the forecast period. The increasing number of patients with autoimmune diseases is driving growth in the market significantly. Middle East and Africa, and Latin America is witnessing moderate growth due to poor healthcare infrastructure.

 Key Players

·         AstraZeneca

·         Radius Health

·         Roche

·         Olema Oncology

·         Oxo Oncology

·         C4 Therapeutics

·         Bristol-Myers Squibb

·         Arvinas

·         Eisai Therapeutics

·         Innocare Pharma

·         Other Players